Skip to content
Buy This GLP
← Research
Safety

Semaglutide and Tirzepatide in Adults 65+: Femoral Fractures and Falls

A matched one-year records study found fewer recorded falls and femoral fractures with semaglutide or tirzepatide than with DPP-4 inhibitors in older adults with type 2 diabetes.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team5 min read
One year, adults 65+ — semaglutide vs DPP-4 drugsfallsHR 0.6633.6%5.4%femoral fractureHR 0.4880.25%0.52%Top bar: semaglutide. Bottom bar: DPP-4 inhibitor.

What the one-year records showed

The researchers used TriNetX health records from 2018 to 2025 and ran two separate matched comparisons. The semaglutide and DPP-4 inhibitor groups each had 27,896 adults. The tirzepatide and its DPP-4 inhibitor groups each had 12,808. Femoral fractures were coded fractures of the thigh bone, which include hip fractures and fractures elsewhere in the femur [1].

The femoral fracture hazard ratio was 0.488 for semaglutide versus DPP-4 inhibitors (95% confidence interval 0.367–0.649). For tirzepatide, 24 versus 56 people had a recorded fracture, about 2.5 fewer per 1,000, with a hazard ratio of 0.452 (95% CI 0.280–0.729) [1]. The hazard ratios compare how quickly the outcome occurred over follow-up. The observed counts show how common the recorded outcome was in each group.

Falls were more common. They were recorded in 3.6% of the semaglutide group and 5.4% of its comparator group (hazard ratio 0.663, 95% CI 0.612–0.718), and in 3.6% of the tirzepatide group and 5.7% of its comparator group (hazard ratio 0.664, 95% CI 0.591–0.747). The absolute gaps in recorded falls were about 18 and 21 per 1,000, respectively, using the rounded rates [1].

What the comparison cannot establish

The main analysis required continued prescriptions between months six and twelve. That can favor people who tolerated treatment or remained in care. The associations were smaller in an analysis that allowed discontinuation and switching, particularly for tirzepatide and fractures. Research on GLP-1 medicines and bone health includes studies that measure bone density directly. This study lacked detailed measures of bone mineral density, frailty and exercise [1].

The study excluded people with recorded falls, femoral fractures, frailty or sarcopenia in the prior year. Its semaglutide analysis did not find clear evidence that the fracture association differed by BMI category (interaction P = 0.29) [1]. Studies of lean mass changes during GLP-1 treatment address a different outcome. These one-year records do not show why falls differed between the groups or how the drugs affect bone over longer periods.

Frequently asked

Did semaglutide halve fracture risk?
In the records study, the hazard ratio for femoral fracture was 0.488. The observed counts were 70 versus 145 among 27,896 people per group, about 2.7 fewer recorded fractures per 1,000 people. The study cannot establish that semaglutide prevented those fractures.
What did the study find about falls?
Falls were recorded in 3.6% of semaglutide users versus 5.4% of their comparison group, and in 3.6% of tirzepatide users versus 5.7% of their comparison group.
Do the findings apply to adults without type 2 diabetes?
The study included adults aged 65 or older with type 2 diabetes and a BMI of at least 25. The results do not establish what happens in other populations.

Sources

  1. [1] Chen HY, Wu JY, Chu YH, Chen TW, Huang CF (2026). Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes Osteoporosis International. PMID 42435064

More in Safety